Description
Ribociclib, marketed under the brand name KISQALI, It is an prescription medication that has been approved ribociclib (Kisqali) on March 13, 2017 for the treatment of advanced or metastatic breast cancer in postmenopausal women. The FDA granted the application a priority review and breakthrough therapy designation.
What is KISQALI (Ribociclib) ?
KISQALI tablets are taken orally with or without food in combination with letrozole. Recommended starting dose: 600 mg orally (three 200 mg tablets) taken once daily with or without food for 21 consecutive days followed by 7 days off treatment. Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability.
How to order approved “KISQALI (Ribociclib) for tablets” Medicine?
KISQALI (Ribociclib) is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing KISQALI and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
